 Connection
Yuwen Zhu to Humans
This is a "connection" page, showing publications Yuwen Zhu has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.244 |
|
|
|
-
Torphy RJ, Yee EJ, Schulick RD, Zhu Y. Atypical chemokine receptors: emerging therapeutic targets in cancer. Trends Pharmacol Sci. 2022 12; 43(12):1085-1097.
Score: 0.023
-
Torphy RJ, Sun Y, Lin R, Caffrey-Carr A, Fujiwara Y, Ho F, Miller EN, McCarter MD, Lyons TR, Schulick RD, Kedl RM, Zhu Y. GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models. Nat Commun. 2022 01 10; 13(1):97.
Score: 0.022
-
Fujiwara Y, Torphy RJ, Sun Y, Miller EN, Ho F, Borcherding N, Wu T, Torres RM, Zhang W, Schulick RD, Zhu Y. The GPR171 pathway suppresses T cell activation and limits antitumor immunity. Nat Commun. 2021 10 06; 12(1):5857.
Score: 0.021
-
Sun Y, Chen W, Torphy RJ, Yao S, Zhu G, Lin R, Lugano R, Miller EN, Fujiwara Y, Bian L, Zheng L, Anand S, Gao F, Zhang W, Ferrara SE, Goodspeed AE, Dimberg A, Wang XJ, Edil BH, Barnett CC, Schulick RD, Chen L, Zhu Y. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. Sci Transl Med. 2021 07 28; 13(604).
Score: 0.021
-
Torphy RJ, Schulick RD, Zhu Y. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. Mol Carcinog. 2020 07; 59(7):775-782.
Score: 0.019
-
Fujiwara Y, Sun Y, Torphy RJ, He J, Yanaga K, Edil BH, Schulick RD, Zhu Y. Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity. Cancer Res. 2018 12 01; 78(23):6655-6665.
Score: 0.017
-
Torphy RJ, Schulick RD, Zhu Y. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. Int J Mol Sci. 2017 Dec 06; 18(12).
Score: 0.016
-
Xu F, Sunderland A, Zhou Y, Schulick RD, Edil BH, Zhu Y. Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunol Immunother. 2017 Oct; 66(10):1367-1375.
Score: 0.016
-
Zhu Y, Paniccia A, Schulick AC, Chen W, Koenig MR, Byers JT, Yao S, Bevers S, Edil BH. Identification of CD112R as a novel checkpoint for human T cells. J Exp Med. 2016 Feb 08; 213(2):167-76.
Score: 0.014
-
Byers JT, Paniccia A, Kaplan J, Koenig M, Kahn N, Wilson L, Chen L, Schulick RD, Edil BH, Zhu Y. Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1574-9.
Score: 0.013
-
Zhu Y, Chen L. CD137 as a biomarker for tumor-reactive T cells: finding gold in the desert. Clin Cancer Res. 2014 Jan 01; 20(1):3-5.
Score: 0.012
-
Zhu Y, Yao S, Iliopoulou BP, Han X, Augustine MM, Xu H, Phennicie RT, Flies SJ, Broadwater M, Ruff W, Taube JM, Zheng L, Luo L, Zhu G, Chen J, Chen L. B7-H5 costimulates human T cells via CD28H. Nat Commun. 2013; 4:2043.
Score: 0.012
-
Zhu Y, Yao S, Chen L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity. 2011 Apr 22; 34(4):466-78.
Score: 0.010
-
Zhu Y, Chen L. Turning the tide of lymphocyte costimulation. J Immunol. 2009 Mar 01; 182(5):2557-8.
Score: 0.009
-
Palmer WH, Leaton LA, Campos Codo A, Crute B, Roest J, Zhu S, Petersen J, Tobin RP, Hume PS, Stone M, van Bokhoven A, Gerich ME, McCarter MD, Zhu Y, Janssen WJ, Vivian JP, Trowsdale J, Getahun A, Rossjohn J, Cambier J, Loh L, Norman PJ. Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells. Sci Immunol. 2023 06 30; 8(84):eade5343.
Score: 0.006
-
Zhu Y, Chen L. Cancer therapeutic monoclonal antibodies targeting lymphocyte co-stimulatory pathways. Curr Opin Investig Drugs. 2003 Jun; 4(6):691-5.
Score: 0.006
-
Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov. 2013 Feb; 12(2):130-46.
Score: 0.003
-
Yao S, Zhu Y, Zhu G, Augustine M, Zheng L, Goode DJ, Broadwater M, Ruff W, Flies S, Xu H, Flies D, Luo L, Wang S, Chen L. B7-h2 is a costimulatory ligand for CD28 in human. Immunity. 2011 May 27; 34(5):729-40.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|